PCSK9 and neoplasm: Similarly, targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a cholesterol metabolism regulator, through gene editing or neutralising antibodies, can increase MHC I expression on tumour cells, enhancing T cell‐mediated tumour killing [25].